Nisa Investment Advisors, LLC Atara Biotherapeutics, Inc. Transaction History

Nisa Investment Advisors, LLC

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 01, 2024	SELL	$0.44 - $1.22 $13 - $36	-30 Reduced 37.5%	50 $0
Q4 2023 Jan 25, 2024	SELL	$0.23 - $1.74 $166 - $1,256	-722 Reduced 90.02%	80 $0
Q3 2023 Nov 02, 2023	BUY	$1.41 - $2.31 $115 - $189	82 Added 11.39%	802 $1,000
Q2 2023 Aug 11, 2023	SELL	$1.5 - $3.04 $1,095 - $2,219	-730 Reduced 50.34%	720 $1,000
Q1 2023 May 02, 2023	SELL	$2.8 - $5.46 $8,119 - $15,834	-2,900 Reduced 66.67%	1,450 $4,000
Q4 2022 Feb 02, 2023	SELL	$2.85 - $5.18 $6,013 - $10,929	-2,110 Reduced 32.66%	4,350 $14,000
Q3 2022 Nov 07, 2022	BUY	$2.85 - $8.73 $16,558 - $50,721	5,810 Added 893.85%	6,460 $28,000
Q1 2022 Apr 29, 2022	BUY	$8.44 - $16.89 $5,486 - $10,978	650 New	650 $6,000
Q4 2021 Feb 03, 2022	SELL	$14.7 - $19.89 $67,914 - $91,891	-4,620 Closed	0 $0
Q4 2020 Jan 25, 2021	BUY	$12.67 - $26.23 $50,046 - $103,608	3,950 Added 589.55%	4,620 $91,000
Q3 2020 Oct 20, 2020	BUY	$11.92 - $15.87 $2,860 - $3,808	240 Added 55.81%	670 $9,000
Q1 2020 Apr 17, 2020	BUY	$5.69 - $17.78 $1,138 - $3,556	200 Added 86.96%	430 $4,000
Q3 2018 Oct 16, 2018	BUY	$35.05 - $43.5 $8,061 - $10,005	230 New	230 $10,000

2.89M

Ticker ATRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,362,304
Market Cap $1.08B
Description
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...

Get notified when there are updates to the investment portfolio of Nisa Investment Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Nisa Investment Advisors, LLC with notifications on news.